33^rd Experts Meet On Cancer Research & Therapy

Bradford has a PhD in Medical Biochemistry-Oncology from the Roswell Park Cancer Institute, Division of SUNY at Buffalo School of Medical and Biomedical Sciences. She is the inventor of the various patents that AccuTheranostics holds. She was awarded the Award for Excellence in Research from the American Federation for Clinical Research, has authored many scientific papers and book chapters, and been an invited speaker at various international scientific meetings. Dr. Bradford is a member of many major professional cancer organizations including, ASCO, AACR and AAAS. As Chief Scientific Officer, Dr. Bradford guides the day-to-day research directives as well as the clinical laboratory operations.

Management, Oncology, Life Science

Liane Deligdisch graduated Medical School in Bucharest, Romania, trained in Obstetrics-Gynecology and Pathology in Israel. In the USA since 1986 she was a resident in Pathology at the Boston Free Hospital for Women (Harvard Medical School) visiting Professor at Magee Women's Hospital, Pittsburgh and Fellow in Perinatal Pathology at the Mount Sinai School of Medicine, New York where she is a Professor of Pathology and Obstetrics-Gynecology since 1986 to present. She founded the Division of Gynecologic Pathology and the Course of Gynecologic Pathology at the Medical School. Member of the French National Academy of Medicine, authored 145 articles in peer-reviewed journals and edited 7 textbooks.

Gynecology, Obstetrics-Gynecology, Gynecologic Pathology

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Acupunture & Electro-Therapeutics Research, Integrative Oncology

Samir A Farghaly is a Physician/Scientist, and faculty member of the Medical College of Cornell University and The New York Presbyterian Hospital /Cornell University Medical Center, New York, NY, USA. He received his M.D Degree from University College London University (1985), and his PhD Degree in molecular biology from London university (1993). He received several clinical and research awards. He has been an invited speaker in several national and international conferences on cancer. He is a member of several national and international societies, organization and foundation of cancer and women health . He is an editor, member of editorial boards and reviewers of several medical journals of Oncology, Gynecology and Gynecological Cancers. He has published 74 articles. He is an editor of a book on ovarian cancer.

Bio markers profile, and screening for ovarian cancer. Mutant BRCA1 and BRCA2 genes profiles in ovarian cancer. Proteomic profiling of metastatic genes of ovarian cancer. Targeted molecular therapy for advanced epithelial ovarian cancer. Minimally invasive surgery for gynecological cancer.

George G Chen is a professor in the Department of Surgery, Director of Surgical Research Laboratories, the Chinese University of Hong Kong, Hong Kong, China. He is also served as a principle investigator at the Hong Kong Cancer Institute. He has extensive experience in cancer research, particularly in the area of apoptosis in hepatocellular carcinoma, lung caner and thyroid cancer. He has authored or co-authored ~120 papers and has written a number of books or book chapters. He is currently a member of editorial boards or a guest editor of a number of scientific journals and a regular peer-reviewer for several grant agents. He was educated in China and United Kingdom and has MB and PhD degrees.

Apoptosis in cancer (hepatocellular carcinoma, lung cancer and thyroid cancer).

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has 450+ peer-reviewed papers, 9 books, has successfully supervised 29 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J. Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD. Her h index =54

Biomedical Sciences

Michael Retsky (Ph.D in physics from University of Chicago) made a career change from physics to cancer research. He is Editor-in-Chief of Journal of Bioavailability and Bioequivalence, on staff at Harvard School of Public Health, honorary faculty at University College London, and Prof Adj at UANL, Monterrey, Mexico. He was on Judah Folkman’s staff at Harvard Medical School for 12 years. He is on the board of directors of the Colon Cancer Alliance and has published more than 60 papers in physics and cancer. He has a patent pending for treatment of early stage cancer.

Cancer research, Charged particle optics and Early detection of cancer and delayed detection of cancer.

Yoshiaki Omura received both Oncology Residency Training and a Doctor of Science Degree through research on Pharmaco-Electro Physiology of Single Cardiac Cells in vivo and in vitro from Columbia University. He has published over 250 articles and 7 books. He is Executive Editor of Integrative Oncology & Editorial Board Member of Journal of Clinical Trials in Cardiology, etc. Using his new diagnostic method, which received U.S. patent, he can non-invasively and rapidly measure many neurotransmitters, other chemicals, asbestos, viruses, and bacteria. He developed non-invasive quick diagnostic methods of malignancies, as well as a method of evaluating the effects of any treatment.

Acupunture & Electro-Therapeutics Research, Integrative Oncology

Dr. Sell is a board certified pathologist and immunologist. He has published over 400 papers and 12 books. His paper with Barry Pierce (Lab. Invest. 70:6-21, 1994.) was selected as an AACR scientific landmark. Among his findings are: development of delayed hypersensitivity before antibody formation (1959). the role of the thymus in development of immune competence (1964); first identification of immunoglobulin on the surface of B cells (1965; Current contents citation classic, 1984); classification of immunopathological reactions (1971); development of a radioimmunoassay for alphafetoprotein (1972); identification of liver stem cells during chemical hepatocarcinogenesis and in response to injury (1972-94); role of endocytosis in activation of B cells (1974); recognition that the chancre of syphilis is a delayed hypersensitivity reaction (1979); role of mGSTA3 in detoxification of aflatoxin (2004); and characterization of breast cancer stem cells (2012).

Cancer: To determine how bone marrow derived mesenchymal stem cells influence the development of cancers in other tissues. Cancer: To block proliferation of breast cancer stem cells by small molecular inhibitors or inhibitory RNA. This is a critical step to preventing re-growth of breast cancer after chemotherapy or radiation therapy. Carcinogenesis: To study the metabolism of aflatoxin and development of liver cancer in mice lacking glutathionine-S-transferase. Aging: To compare the ability of young vs. old bone marrow derived stem cells to reconstitute and provide long term survival after lethal irradiation and transplantation, and the ability of wild-type bone marrow to prolong life of early aging mice.

Dr Massimo Cecaro after completing the high school in humanistic studies, he moved to the University of Camerino, where he got a Master Degree in Veterinary Medicine and in University of Teramo he successfully got the Specialization. Since the age of 14, he has worked as radio speaker, tv presenter and reporter for a wide range of artistic and scientific events. At the age of 24 he obtained a qualification to practice as a Journalist and in 2007 he was admitted to the National Association of Medical Press (ASMI), where he currently hold the position of National Councilor. He is Resident Member of MJA Medical Journalists’ Association (London). He is Member of EFSA's Expert Database. He has been an invited speaker,mentor and chairman at International events in the field of Public Health and Safety in Canada, US, Europe and Asia. He has been author of several scientific works in public health. He is also director in Italy of a prestigious Educational Centre for work safety and public health. He is actively involved in international projects to improve the role of mass-media in medical sciences, and awarded in Philadelphia, Valencia and Las Vegas with International special recognition. He is serving as an editorial member of several reputed journals like: “Journal Food Processing Technology”, “Journal of Veterinary Science & Technology”, and Editor in Chief in the “Occupational Medicine & Health Affairs” and in “Journal of Mass Communication”. He is Reviewer for "Journal od Cancer Science & Therapy”. He is Organizing Commette Member of several International Conferences in US and in Europe.

Medical and scientific communication, risk analysis, Epidemiology, Work safety, Food safety, Anthropozoonoses and comparative oncology

Mukesh Verma is Chief of the Epidemiology and Genomics Research Program′s (EGRP). Dr. Verma joined EGRP as a Program Director in 2004. In 2005, he was appointed Acting Chief of EGRP′s former Analytic Epidemiology Research Branch (AERB). When EGRP reorganized in 2007, he was appointed Acting Chief of MTB and of the Host Susceptibility Factors Branch (HSFB), for which he served as Acting Chief through 2008. Before joining EGRP, he was a Program Director in NCI′s Division of Cancer Prevention (DCP). He also was Coordinator of DCP′s Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs. He was on the faculty in the Biochemistry Department of Georgetown University before joining NIH.

Biomarkers, epigenetics, epidemiology technologies, proteomics, microRNA, methylation, mitochondria, nanotechnology, risk assessment, susceptibility factors, and systems genetics.

Homer S. Black is a Professor of Dermatology, Baylor College of Medicine, Houston, Texas (1968- 2003).He is a  Research Physiologist and Director of the Photobiology Laboratory at the Veterans Affairs Medical Center in Houston. Dr. Black earned a Ph.D. in biochemistry from Louisiana State University in 1964. He earned a B.Sc. in animal science from Texas A&M University in 1956 after which he served with the U.S. Air Force in Strategic Air Command and  holds a M.Ed. from Sam Houston State University; and a M.S.Admin. (business/health science management) from the University of Houston. He was a Senior Fulbright Scholar at the Photobiology Centre, University of Dundee, Scotland. . He served as Treasurer in the latter. Dr. Black is also a member of the Institute of Professional Managers and was Chairman of the Board of Regents for the Academy of Administrative Managers.

Pro-carcinogenic effects of antioxidants and dietary fat in UV-carcinogenesis. The experimental studies culminated in a dietary intervention trial in which it was shown that a low-fat dietary intervention reduced the risk for subsequent skin cancers in skin cancer patients.

Vural Fidan has recieved his MD and PhD in Hacettepe University. He is deputy director of ENT department. He is an Otorhinolaryngologist at Yunus Emre Goverment Hospital. He worked as a visiting scientist at Yale University ENT and Allegry departments. He has more than 20 SCI indexed articles. Research interests are pulmonary hypertension, allergy, otology, rhinology and sleep medicine.

Allergic Rhinitis and Immunology
Facial Plastic Surgery
Congenital Hear Loss

The central theme of Gary Stein’s research has been to discover mechanisms controlling proliferation and differentiation emphasizing compromised regulation linked with disease.  His lab characterizes transcriptional regulation that mediates cell cycle control, focusing on molecular mechanisms regulating gene expression at the G1/S phase transition in normal and tumor cells and the abbreviated pluripotent cell cycle in human embryonic stem cells.  He has a major commitment to investigating bone tissue specific gene expression, including microRNA-mediated control, within the context of skeletal development and bone remodeling as well as aberrations that accompany the onset and progression of skeletal disease.  The Stein lab is defining functional relationships between the subnuclear organization of regulatory proteins and gene expression, pursuing mechanisms that support combinatorial organization and assembly of regulatory machinery in nuclear microenvironments and epigenetic control of cell fate and lineage commitment in biological control and cancer.

Professor
University of Massachusetts Medical School
USA

Bradford has a PhD in Medical Biochemistry-Oncology from the Roswell Park Cancer Institute, Division of SUNY at Buffalo School of Medical and Biomedical Sciences. She is the inventor of the various patents that AccuTheranostics holds. She was awarded the Award for Excellence in Research from the American Federation for Clinical Research, has authored many scientific papers and book chapters, and been an invited speaker at various international scientific meetings. Dr. Bradford is a member of many major professional cancer organizations including, ASCO, AACR and AAAS. As Chief Scientific Officer, Dr. Bradford guides the day-to-day research directives as well as the clinical laboratory operations.

President, CSO and Founder
AccuTheranostics, Inc.,
USA

Dr. Phillips is a national leader in the treatment of hematologic malignancies and is an innovator in bringing transplant modalities to lymphoma. He is a graduate of the University of Oklahoma School of Medicine where he completed his internship in internal medicine. He continued his residency training at the University of North Carlina School of Medicine and trained at Washington University School of Medicine with a clinical and research fellowship in hematology/oncology. He previously directed the transplant programs at the University of Maryland, University of Kentucky, theUniversity of British Columbia, and Barnes Hospital at the Washington University School of Medicine. Dr. Phillips was the principal investigator of the National Cancer Institute (NCI) study "Improving the Ability of (High-Risk) Hematologic Malignancy Patients to Undergo Allogenic Stem Cell Transplantation".

Hematologic malignancies, Allogenic Stem Cell Transplantation,Internal medicine,Lymphoma.

Kandace Williams is a Professor in the Department of Biochemistry, Cancer Biology at the University of Toledo College of Medicine since 2001.  She was formerly a faculty member at the University of Alaska Biomedical Program.  Her postdoctoral fellowship was with Dr. Lawrence Loeb in the Department of Pathology at the University of Washington School of Medicine. She is currently affiliate faculty in the Department of Pathology.  She received her PhD from the Department of Pharmacology and Toxicology at Dartmouth Medical School and her BS Cum Laude at the University of Alaska Anchorage. She has served on the NIH Cancer Etiology and Chemical Pathology study sections for several years is on the Editorial Board of Mutation Research and a Board member of American Society for Circumpolar Health as well as Council member of the Environmental Mutagen Society. She also serves in the UTCOM Institutional Review Board for Human Research Cancer Biology PhD Program, Steering Committee Cancer Center Program, Director  of Cell Biology and Pathogenesis section.

Mechanisms of DNA damage and repair of alkylating agents.Base excision and mismatch repair within different phases of the cell cycle. Mismatch repair-induced DNA damage response and cell cycle effects.DNA damage response effects on replication factories.

Dental School University of Medicine and Dentistry of New Jersey 110 Bergen Street Newark.

Oral Biology.

Mitchell Ho is an Investigator and Head of the Antibody Therapy Unit in the Laboratory of Molecular Biology at the National Cancer Institute (NCI). Dr. Ho received his Ph.D. from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award Fellow with Mariangela Segre. He completed postdoctoral studies with Ira Pastan at the NCI working on immunotoxin therapy of cancer. Research in Dr. Ho’s laboratory studies mesothelin, CA125/MUC16 and other cell adhesion molecules as therapeutic targets in order to develop novel antibodies and immunoconjugates to treat ovarian cancer, mesothelioma and liver cancer. He has developed the mammalian cell display method which is currently being used by investigators worldwide to identify and engineer therapeutic antibodies. Dr. Ho is a recipient of Mesothelioma Applied Research Foundation Award, and Ovarian Cancer Research Fund Individual Investigator Award.

Ovarian cancer, liver cancer.

Frederick Domann is a Professor of Radiation Oncology in the Free Radical Radiation Biology Program at The University of Iowa in Iowa, USA . He earned his PhD from the University of Wisconsin, Madison in Human Cancer Biology under the mentorship of Kelly H Clifton and subsequently carried out postdoctoral research at The Arizona Cancer Center with G Tim Bowden. He joined the faculty at The University of Iowa in 1993 and has become an internationally recognized expert in and free radical biology and cancer.

Transcriptional regulation ,Free radical biology ,Metabolism ,Epigenetic control of gene expression in human cancer.

Demir Akin Congretionally Directed Medical Research Programs, Breast Cancer Research Program, National Cancer Institute, Alliance for Nanotechnology in Cancer,  Radiation Oncology Program, CDMRP/DoD,  American Association for Cancer Research (AACR), U.S. Civilian Research and Development Foundation (CRDF).

Biological Engineering and Micro/Nanomedicine, Genomics/Systems Biology, Gene Therapy/Microbiology/Virology.

Hilal Arnouk, MD, PhD. is currently a professor at Georgia State University. Dr. Arnouk has received his education and post-doctorate training at Roswell Park Cancer Institute, Medical College of Georgia and University of Alabama at Birmingham. His major areas of expertise include Cancer Biology, Tumor Immunotherapy and Biomarker Discovery.

Cancer Biology, Tumor Immunotherapy and Biomarker Discovery.

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013-); Visiting Professor in Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, TX, USA (2012–2013); Visiting Professor in Department of Pathobiology, College of Veterinary Medicine, The University of Missouri-Columbia, MO, USA (2012); Visiting Professor in Department of Foods and Nutrition, The University of Georgia, GA, USA (2011 – 2012); Visiting Professor in Division of Endocrinology and Metabolism and Lipids, Department of Medicine, Emory University School of Medicine, GA, USA (2007 – 2011); Professor in Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1993 ~ August 2007); Associate Professor in Graduate School of Nutritional Sciences, University of Shizuoka, Japan (1991~1993); Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka, Japan (1987~1991); Visiting Assistant Professor in The University of Texas Medical School at Huston, USA (1988); Assistant Professor in Shizuoka College of Pharmacy, Japan (1986~1987); Visiting Assistant Professor in Texas Tech University School of Medicine, USA (1985); Visiting Lecturer in The University of Pennsylvania School of Medicine, USA (1981); Research Associate in Shizuoka College of Pharmacy, Japan (1973 ~ 1986). He received a Ph.D. in Pharmaceutical Sciences from Shizuoka College of Pharmacy (1976, Japan). He has completed his B.S. in Pharmaceutical Sciences, Shizuoka, Japan (1971). Dr. Yamaguchi is engaged in the fields of bone and calcium endocrinology and cell calcium signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr. Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetic osteoporosis, and cancer bone metastasis and osteolysis. Moreover, Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001) in mammalian cells. Dr. Yamaguchi generated regucalcin transgenic rats, which were registered as international patents (USA, EU, Japan, and Korea), and this animal is found to induce osteoporosis and hyperlipidemia. Recently, Dr. Yamaguchi proposes that regucalcin is a target molecule in carcinogenesis of various cancer cell types. Currently, the research of regucalcin is focused as a scientific topic. Dr. Yamaguchi published over 500 English articles to professional journals with peer-review. In addition, Dr. Yamaguchi registered over 20 national and international patents in the fields of his research interesting. Dr. Yamaguchi is serving as editors and editorial board members of reputed 40 international Journals. He received many honor and awards; Prize for Sato Memorial Fundation (1992, Japan/USA), Senji Miyata Foundation Award 2005 (Japan), Japan Society for Biomedical Research on Trace Elements Award 2007, The Lifetime Achievement Award from International Biographical Centre (IBC) (2004, England), The World Lifetime Achievement Award from American Biographical Institute (2004, USA), The Distinguished Service to Science Award from IBC (2007, England), and many others. Dr. Yamaguchi is listed in various biographies; Who’s Who in the World (2005-, Marquis Who’s Who, USA), Who’s Who in Sciences and Engineering (2004-, Marquis Who’s Who, USA), International Biographical Dictionary (2006-, IBC, England), and others.

Cancer and Oncology, Toxicology, Pharmacology

Dr. Notario’s expertise in Experimental Molecular Carcinogenesis has been recognized also through invitations to participate in U.S. and international scientific review and advisory committees, such as those for the U.S. National Institutes of Health, the American Association for Cancer Research, the U.S. Department of Defense, the Israel Science Foundation, the Italian National Center for Rare Diseases, the Italian Association for Research on Cancer, and the Department of Education and Science of Spain. In addition, Dr. Notario has been invited to act as an ad hoc expert reviewer for over 50 specialized U.S. national and international scientific journals. His service to Georgetown University included terms in the G.U.M.C. Research Committee and various faculty search committees, the Medical School Admissions Committee and the Lombardi Comprehensive Cancer Center Executive Committee, and is currently serving as Chairman of the Georgetown Institutional Biosafety Committee.

Biochemistry, Molecular Biology, Radiation Biology, Molecular Carcinogenesis and Tumor Biology.

Chulso Moon is having 1. Tenure Track Professorship in the Department of Oncology, Otolaryngology, Head and Neck Surgery, The Johns Hopkins University School of Medicine (2001-2007). 2. Principal Investigator, The Head and Neck Cancer Research Institute, The Johns Hopkins University School of Medicine (Director: Dr. David Sidransky) (2001-). 3. Attending physician, The Johns Hopkins Hospital (2001-2006). 4. Principal investigator, ONXY-015 cancer genetherapy program for advanced head/neck cancer (2001-2003). 5. Adjunct Professorship, Department of Otolaryngology and Head and Neck Surgery, The Johns Hopkins University school of Medicine (2008- Present). 6. Preceptor, Graduate Program in Human Genetics and Molecular Biology, The Johns Hopkins University school of Medicine (2005- Present, Thesis Advisor for Juna Lee, 2010 Ph.D. Candidate). 7. Director of Medical Oncology, Cleo Craig Memorial Cancer Clinic, The South-Western Medical Center, Lawton OK (2010-Present).

Cancer gene therapy.

Mong-Hong Lee is currently Professor in the Department of Molecular and Cellular Oncology of University of Texas MD Anderson Cancer Center and a faculty member at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS). In 1993, Dr. Lee received his Ph.D. degree in Molecular, Cellular, and Developmental Biology from the University of Pittsburgh, where he received the Stanton C. Crawford Award for teaching excellence. He then went on to complete a postdoctoral fellowship while serving as a research associate at Howard Hughes Medical Institute and Memorial Sloan-Kettering Cancer Center (1993-1997).  After completing his fellowship, Dr. Lee came to M. D. Anderson in 1997 as an Assistant Professor (tenure track). He was promoted to his current position of Professor (tenured) in 2010. During his time at M. D. Anderson, Dr. Lee has been the principal investigator or a co-principal investigator for nine funded research projects. He also has been a grant reviewer for several funding agencies. Dr. Lee has been honored for his research activities, led by the Susan G. Komen Breast Cancer Foundation Research Award (2001), Fleming and Davenport Research Award (2001), and William G. McGowan Foundation Research Award (1998). In addition to research, for more than a decade, Dr. Lee has been a key contributor to the education of trainees at M. D. Anderson and the GSBS in a variety of ways. For example, at the GSBS, he has been the course coordinator for the Molecular Genetics of Human Cancer seminar since 2006 and an instructor for the Cancer Cell Signaling course since 2000. Dr. Lee has had a wealth of direct interaction with trainees throughout his career. Specifically, he has directly supervised 40 graduate students, 12 clinical residents and fellows, 12 undergraduate and Allied Health students, 9 postdoctoral research fellows, and 1 medical student. Furthermore, he has chaired or served on 71 examining committees, 67 advisory committees, and 39 supervisory committees. UT M. D. Anderson Cancer Center and the UT GSBS at Houston have well recognized Dr. Lee’s educational efforts. In 2009, he received the John P. McGovern Outstanding Teaching Award, which is given annually to a faculty member at M. D. Anderson and/or the GSBS. Most recently, he has recently been named the February 2010 Faculty Educator of the Month at MD Anderson Cancer Center. Also, he received the M. D. Anderson Outstanding Educator Award in 2003. Currently, Dr. Lee is an ad hoc reviewer for 25 journals. He also has been a guest editor for the journal Breast Diseases. Over the course of his career, Dr. Lee has authored more than 50 articles published in peer-reviewed journals, 4 book chapters, and 3 invited articles

Characterizing the roles of Cdk inhibitors (CKIs) in cancer formation, and exploiting signaling regulation in cancer therapy. Research projects focusing on: 1) roles of two CKI molecules that he cloned in tumorigenesis; 2) COP9 signalosome signaling regulation; 3) investigating the impact of hypoxia and PIm1 kinase in drug resistance; 4) employing Aurora B kinase inhibitor for cancer therapy; 5) p53-MDM2 signaling regulation and DNA damage; 6) Myc ubiquitination regulation; 7) Glycolysis and cancer metabolism.

Reza Hakkak, Ph.D., is nutritionist and Professor and Chairman of the Department of Dietetics and Nutrition in the College of Health Professions, Professor of Pediatrics in the College of Medicine, and Professor of Department of Health Policy and Management in the College of Public Health at the University of Arkansas for Medical Sciences. Dr. Hakkak’s research includes Nutritional toxicology, Influence of diet and nutrition on cancer prevention or promotion, Obesity and Breast Cancer prevention or promotion, Animal modeling for Cancer Research. Dr. Hakkak has published more than 45 research articles and more than 170 abstracts and presentations. He is the Editor in chief for Obesity and Weight Loss Therapy and Vitamins and Minerals and also serves as senior editor for Journal Cancer Science and Therapy. Dr. Hakkak also serves on another 10 editorial boards of other journals.

Reza Hakkak is Professor in the Department of Dietetics and Nutrition, University of Arkansas for Medical Sciences. He is nutritionist, Professor of Pediatrics in the college of Medicine, and Maternal Child Health in the College of Public Health.

Dr. Jimmy Efird is an Associate Member of the Leo Jenkins Cancer at Brody School of Medicine. Additionally, he holds a joint appointment as Associate Professor in the Department of Public Health and as Epidemiologist/Chief Statistician (Director, Shared Resources) in the Center for Health Disparities. Dr. Efird received his Ph.D. from Stanford University (Epidemiology with a concentration in Biostatistics). His expertise includes statistical methods for assessing gene-environment interaction, clinical trial design, computing power and sample size for correlated samples, and multiplicity adjustment for confidence intervals. He has over 100 publications in scientific journals and technical proceedings. Additionally, Dr. Efird serves as a Senior Consultant for The NCRR-funded RCMI Translational Research Network Data and Technology Coordinating Center.

Genetic epidemiology, cancer informatics, brain tumors, soft-tissue sarcomas, and HPV-related cancers. Additionally, he is founding co-chair for the advances in Bioinformatics and Genomics Symposium series. Dr. Efird has over 100 publications in scientific journals and proceedings.

Liang Xu is an Associate Professor in the Department of Molecular Biosciences at University of Kansas

Molecular therapy targeting cancer and cancer stem cells, cancer biology, drug discovery and drug/gene delivery. Funded by multiple NIH and DOD grants, his lab is working on molecularly targeted cancer therapy and chemo/radiosensitization by modulating cell death signaling pathways, autophagy and apoptosis. We are exploring microRNAs as novel targets for cancer and cancer stem cells. Novel nanotechnology to develop nanovectors targeting cancer stem cells and exploring novel molecular therapy for cancer stem cells.

Itzhak Avital, MD, PhD, MBA, FACS, is an established surgical oncologist and Chairman of the Department of Surgery at Saint Peter’s University Hospital in New Brunswick, New Jersey. “Dr. Avital is an experienced and innovative healthcare administrator”, said Ronald C. Rak, CEO of Saint Peter’s Healthcare System, on Dr. Avital’s appointment as Chair of Surgery. “Among his achievements he has constructed multidisciplinary disease management teams, built a clinical trial unit, established a research division, led cancer operations encompassing multiple hospitals, created tumor and gene banks, and led philanthropic efforts to support a cancer institute. We are thrilled he is here”, he adds. Dr. Avital has 15 years of uniquely diversified experience in his specialty and a vast expertise in hepatobiliary surgery and hyper-thermic intraperitoneal chemotherapy treatment. Furthermore, Dr. Avital is the Executive Medical Director of The Bon Secours Cancer Institute in Virginia, which is dedicated to studying and applying the latest evidence-based treatments for cancer of the surface of the peritoneum, the tissue that makes up the inner lining of the abdomen. Dr. Avital performed the first hyper-thermic intraoperative peritoneal chemotherapy (HIPEC) in central Virginia. In addition to his work with Saint Peter’s University Hospital, Dr. Avital is the CEO and Executive Medical Director of P8Medicine in Virginia and Professor of Surgery at Rutgers University/Robert Wood Johnson School of Medicine. He previously served as Head of the Gastroenterology and Hepatobiliary Malignancies Section, Surgery Branch, at the National Cancer Institute between 2006 and 2012. His international background includes his roles as Professor of Surgery at the Medical School of the University of Novi Sad in Serbia, Professor of Surgery at the Chinese National Colorectal Cancer Institute in Nanjing, China, and Visiting Professor of Surgery in the Department of Surgery at Hadassah Hospital in Israel. For more information about Itzhak Avital, MD, PhD, MBA, FACS.

Surgical Oncology

Acquired about 20-years of belly-to-the bench experience in the microbiology and chemistry laboratory. He specialized in CANNABIS TESTING, FOOD TESTING, ENVIRONMENTAL TESTING, CHEMISTRY TESTING, MICROBIOLOGY TESTING and PRODUCT DEVELOPMENT. In addition, he has collaboratively worked with numerous clients to test their product's efficacy at killing bacterial or fungal microbes as well as nutritional labeling and FDA detain needs.He has also acquired a few years of experience teaching lecture and lab at the community college level so I am well respected and trustworthy within your local community. Moreover, he is incredibly savvy at respecting client confidentiality and being readily available to help out 24/7.

Cannabis Testing Expert

Prof. Eric Raymond, M.D., Ph.D. serves as Consultant of Erytech Pharma Société Anonyme. Prof. Raymond serves as a Consultant of Preclinical and Translational Research France of Cvitkovic & Associés Consultants S.A and AAI Oncology. Prof. Raymond has been Member of Scientific Advisory Board at PharmaEngine, Inc. since January 2017. He has been a Member of Scientific Board of Erytech Pharma Société Anonyme (formerly, ERYtech Pharma SA) since October 30, 2009. He serves as a Member of the Scientific Board of Manros Therapeutics. He is the Head of Medical Oncology at Paris Saint-Joseph Hospital Group. Prof. Raymond is a Professor of Medical Oncology at the University Paris VII (Denis Diderot) and Head of the Department of Medical Oncology (Service Inter Hospitalier de Cancérologie) at Bichat-Beaujon University Hospitals in Paris. He serves as consultant in medical oncology at Bichat Hospital. He was the Principal Investigator of less than 50 clinical trials, including phase I, II and III studies. Some of his works were seminal in the development of phase III trials and registration of some drugs such as oxaliplatin, sunitinib, temsirolimus and everolimus. He has highly regarded expertise in Oncology in clinical and pre-clinical approaches. He has published more than 100 articles and is a member of several international societies of experts in the field of oncology. Prof. Raymond received his M.D. and Ph.D. from Pierre et Marie Curie Paris 6 University, France.

Medical Oncology Immunotherapy Targeted therapy

Dr. Nezami is a board certified physician graduated from USC and UCSF residencies. He has functioned as a faculty teacher during his training as well as invited presenter at society of teachers in Family medicine. He has been in practice for 18 years and currently is the president of Pacific Medical Center of Hope in California. He is promoting research in conventional oncology, in cutting edge. Dr Nezami serves as national and international speaker in oncology and epigenetic science. He has been involved in many research projects and publications, presentations ( including integrative medicine, Epigenetic therapies 2013 Barcelona Conference on Epigenetics and Cancer, Society of integrative oncology, American Association for Cancer Research ( AACR), Molecular Medicine Triconference, World Molecular Imaging, and World Pharmaceutical Congress, NCI-AACR, .... Author, Integrative Medicine, A Clinician Journal, as well as author and coauthor in oncology literature. (Surveillance in lymphoma, published 2006, Cancer Science 2015, JCT 2015, 2016, Precision medicine,.....). He is a co author of Weil’s " Textbook for integrative oncology

Cancer

Dharanipathy Rangaraj has completed his PhD from University of Missouri, Columbia.He is Board Certified Medical Physicist.He has published more than 25 papers in reputed journals and has been serving as an editorial board member of repute

Radiation Oncology

Bogusław Maciejewski has completed his PhD at the age of 32 years and scientific title of a full professor in radiotherapy being 45 years old. He realized research projects in the UCLA Los Angeles, Gray Lab London, MGH Harvard Univ. Boston, MDACC Houston and other cancer centers in Europe. He was the director of Cancer Center – Institute Gliwice, Poland for 24 years, till 2015. He is author of over 200 papers published in reputed journals (IF = 1650, citation index = 3500). He awarded G.F. Fletcher Gold Medal, Gold Medal of Life Achievements in Oncology given by all European oncologic societies as he is a honorary member of American College of Radiology, radiotherapy expert of the IAEA in Vienna and for 10 years he was a member of European Board of Radiotherapy participating in the development European curriculum for radiotherapy. His major scientic interest is importance of treatment time and tumor repopulation and altered dose fractionation in clinical radiotherapy for human tumors.

Radiotherapy

Dr. Ruiz-Gómez, MSc PhD is currently associate professor of Radiobiology and Biomechanics in the Radiology and Physical Medicine Department at University of Málaga, Spain. He is also Director of the Radiobiology Laboratory, www.radiobiologia.uma.es. He has to his credit numerous publications in international journals having h-index: 9 and 221 citations.

Effects of electromagnetic fields. Molecular Radiobiology. Cellular aging. Biological dosimetry.

David Huang finished his BS in physics in National Taiwan Normal University and gained PhD in high energy physics in Temple University, Philadelphia. Before Joining in Duke Kunshan University, Prof. Huang was the chief physicist and RSO, faculty of Memorial Sloan Kettering at Rockville Centre and he was an associate attending physicist in the department of medical physics at MSKCC. Prof. Huang is an adjunct professor at University of Missouri and a visiting professor at MP Program at Tsing-Hwa University, Beijing. He was a visiting professor at Beijing University and an associate professor at Chang-Gung University, Taiwan. Prof. Huang’s research interests include dosimetry and QA in radiotherapy; particularly in in-vivo dosimetry (glass dosimeter), modern radiotherapy techniques (Image-guided intensity-modulated radiotherapy, stereotactic body radiotherapy) and modern radiotherapy modalities (TrueBeam, Gamma Knife, CyberKnife, and Tomotherapy).

Medical Physics

Professor Mohamed El-Far, worked in biochemistry field for 40 years, published over 90 peer-reviewed papers. He received Fullbright and British council fellowships several times as well as German DAAD grant to establish PDT Program at Munchen, also received US-AID grant to establish PDT unit in Egypt. He is serving on the editorial boards and Hon. Editor to three international journals. He acts as UNESCO expert in science and technology. Dr. El-Far served as visiting professor to University of California as well as Utah laser center also Mayo clinic for several years. He also served as a visiting professor to Cardiff and Swansea Universities, UK. He is a member of International Photodynamic Association and Royal Society of Chemistry, UK. Selected recently as expert and consultant for biochemistry in the national committee of suprime council of Universities in Egypt, which is the highest nation honor

Cancer